Azanta completes turnaround and turns deficit to profit

After a million dollar deficit in 2015, the biotech company Azanta ended 2016 with a positive annual result. There are high expectations to the company’s first drug – the birth pill Angusta.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us free for 14 days

Get 14 days free trial access

Frontpage right now

Latest Top picks in English

Related articles